vs
Side-by-side financial comparison of Brookfield Infrastructure Corp (BIPC) and Elanco Animal Health Inc (ELAN). Click either name above to swap in a different company.
Elanco Animal Health Inc is the larger business by last-quarter revenue ($1.1B vs $866.0M, roughly 1.3× Brookfield Infrastructure Corp). Elanco Animal Health Inc runs the higher net margin — -24.1% vs -35.7%, a 11.6% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs -4.6%).
Brookfield Infrastructure Partners L.P. is a publicly traded limited partnership with corporate headquarters in Toronto, Canada, that engages in the acquisition and management of infrastructure assets on a global basis.
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
BIPC vs ELAN — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $866.0M | $1.1B |
| Net Profit | $-309.0M | $-276.0M |
| Gross Margin | 65.0% | 51.5% |
| Operating Margin | 62.7% | -22.6% |
| Net Margin | -35.7% | -24.1% |
| Revenue YoY | -4.6% | 12.2% |
| Net Profit YoY | -148.1% | -3350.0% |
| EPS (diluted) | — | $-0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | $866.0M | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | $908.0M | $1.2B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | — | $-276.0M | ||
| Q3 25 | — | $-34.0M | ||
| Q2 25 | $-309.0M | $11.0M | ||
| Q1 25 | — | $67.0M | ||
| Q4 24 | — | $-8.0M | ||
| Q3 24 | — | $364.0M | ||
| Q2 24 | $643.0M | $-50.0M | ||
| Q1 24 | — | $32.0M |
| Q4 25 | — | 51.5% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | 65.0% | 57.5% | ||
| Q1 25 | — | 57.3% | ||
| Q4 24 | — | 50.9% | ||
| Q3 24 | — | 52.2% | ||
| Q2 24 | 63.8% | 58.2% | ||
| Q1 24 | — | 57.3% |
| Q4 25 | — | -22.6% | ||
| Q3 25 | — | -4.4% | ||
| Q2 25 | 62.7% | 2.0% | ||
| Q1 25 | — | 5.0% | ||
| Q4 24 | — | -5.0% | ||
| Q3 24 | — | 54.3% | ||
| Q2 24 | 61.9% | -2.7% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | -24.1% | ||
| Q3 25 | — | -3.0% | ||
| Q2 25 | -35.7% | 0.9% | ||
| Q1 25 | — | 5.6% | ||
| Q4 24 | — | -0.8% | ||
| Q3 24 | — | 35.3% | ||
| Q2 24 | 70.8% | -4.2% | ||
| Q1 24 | — | 2.7% |
| Q4 25 | — | $-0.55 | ||
| Q3 25 | — | $-0.07 | ||
| Q2 25 | — | $0.02 | ||
| Q1 25 | — | $0.13 | ||
| Q4 24 | — | $-0.01 | ||
| Q3 24 | — | $0.73 | ||
| Q2 24 | — | $-0.10 | ||
| Q1 24 | — | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.2B | $545.0M |
| Total DebtLower is stronger | — | $3.9B |
| Stockholders' EquityBook value | $2.2B | $6.5B |
| Total Assets | $23.9B | $13.4B |
| Debt / EquityLower = less leverage | — | 0.60× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $545.0M | ||
| Q3 25 | — | $505.0M | ||
| Q2 25 | $1.2B | $539.0M | ||
| Q1 25 | — | $487.0M | ||
| Q4 24 | — | $468.0M | ||
| Q3 24 | — | $490.0M | ||
| Q2 24 | $466.0M | $416.0M | ||
| Q1 24 | — | $345.0M |
| Q4 25 | — | $3.9B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | — | $4.1B | ||
| Q1 25 | — | $4.4B | ||
| Q4 24 | — | $4.3B | ||
| Q3 24 | — | $4.4B | ||
| Q2 24 | — | $5.7B | ||
| Q1 24 | — | $5.8B |
| Q4 25 | — | $6.5B | ||
| Q3 25 | — | $6.7B | ||
| Q2 25 | $2.2B | $6.8B | ||
| Q1 25 | — | $6.4B | ||
| Q4 24 | — | $6.1B | ||
| Q3 24 | — | $6.5B | ||
| Q2 24 | $3.5B | $5.9B | ||
| Q1 24 | — | $6.1B |
| Q4 25 | — | $13.4B | ||
| Q3 25 | — | $13.6B | ||
| Q2 25 | $23.9B | $13.7B | ||
| Q1 25 | — | $12.9B | ||
| Q4 24 | — | $12.6B | ||
| Q3 24 | — | $13.3B | ||
| Q2 24 | $23.7B | $13.8B | ||
| Q1 24 | — | $14.0B |
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.69× | ||
| Q4 24 | — | 0.70× | ||
| Q3 24 | — | 0.67× | ||
| Q2 24 | — | 0.96× | ||
| Q1 24 | — | 0.95× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $478.0M | $108.0M |
| Free Cash FlowOCF − Capex | — | $46.0M |
| FCF MarginFCF / Revenue | — | 4.0% |
| Capex IntensityCapex / Revenue | — | 5.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $284.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $108.0M | ||
| Q3 25 | — | $219.0M | ||
| Q2 25 | $478.0M | $237.0M | ||
| Q1 25 | — | $-4.0M | ||
| Q4 24 | — | $177.0M | ||
| Q3 24 | — | $162.0M | ||
| Q2 24 | $511.0M | $200.0M | ||
| Q1 24 | — | $2.0M |
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $127.0M | ||
| Q2 25 | — | $180.0M | ||
| Q1 25 | — | $-69.0M | ||
| Q4 24 | — | $130.0M | ||
| Q3 24 | — | $120.0M | ||
| Q2 24 | — | $166.0M | ||
| Q1 24 | — | $-22.0M |
| Q4 25 | — | 4.0% | ||
| Q3 25 | — | 11.2% | ||
| Q2 25 | — | 14.5% | ||
| Q1 25 | — | -5.8% | ||
| Q4 24 | — | 12.7% | ||
| Q3 24 | — | 11.7% | ||
| Q2 24 | — | 14.0% | ||
| Q1 24 | — | -1.8% |
| Q4 25 | — | 5.4% | ||
| Q3 25 | — | 8.1% | ||
| Q2 25 | — | 4.6% | ||
| Q1 25 | — | 5.4% | ||
| Q4 24 | — | 4.6% | ||
| Q3 24 | — | 4.1% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | 2.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 21.55× | ||
| Q1 25 | — | -0.06× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | 0.79× | — | ||
| Q1 24 | — | 0.06× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIPC
Segment breakdown not available.
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
